UCB's Neupro allowed to be fully available in the EU market
This article was originally published in Scrip
A new cold-store storage and distribution system for UCB's Neupro (rotigotine) transdermal patches has been cleared by the European Medicine Agency's advisory committee, the CHMP, allowing the product to be fully available again, once the positive opinion is approved by the European Commission.
You may also be interested in...
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.